{"organizations": [], "uuid": "72d94a6bb907610f2772209c77b0c685f292a231", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/2", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/01/globe-newswire-aeterna-zentaris-to-announce-first-quarter-2018-financial-and-operating-results-on-may-7-2018.html", "country": "US", "domain_rank": 767, "title": "Aeterna Zentaris to Announce First Quarter 2018 Financial and Operating Results on May 7, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.185, "site_type": "news", "published": "2018-05-02T01:05:00.000+03:00", "replies_count": 0, "uuid": "72d94a6bb907610f2772209c77b0c685f292a231"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/01/globe-newswire-aeterna-zentaris-to-announce-first-quarter-2018-financial-and-operating-results-on-may-7-2018.html", "ord_in_thread": 0, "title": "Aeterna Zentaris to Announce First Quarter 2018 Financial and Operating Results on May 7, 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "s.c.", "sentiment": "none"}, {"name": "charleston", "sentiment": "none"}], "organizations": [{"name": "aeterna zentaris inc.", "sentiment": "negative"}, {"name": "aeterna zentaris", "sentiment": "negative"}, {"name": "company", "sentiment": "none"}, {"name": "aeterna zentaris inc", "sentiment": "none"}, {"name": "strongbridge biopharma", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "CHARLESTON, S.C., May 01, 2018 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) will announce its first quarter 2018 financial and operating results after market close on Monday, May 7, 2018. The Company will host a conference call to discuss these results on Tuesday, May 8, 2018 at 8:30 a.m. Eastern Time.\nParticipants may access the conference call by telephone using the following numbers:\nToll-Free: 877-407-8029, Confirmation #13679691 Toll: 201-689-8029, Confirmation #13679691\nA replay will also be available on the Company’s website for a period of 30 days.\nAbout Aeterna Zentaris Inc.\nAeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing, principally through out-licensing arrangements, Macrilen™ (macimorelin), an orally available ghrelin agonist, to be used in the diagnosis of patients with adult growth hormone deficiency. Aeterna Zentaris has entered into a license and assignment agreement with a wholly-owned subsidiary of Strongbridge Biopharma plc to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada. For more information, visit www.aezsinc.com .\nContact:\nAeterna Zentaris Inc.\nJames Clavijo\nChief Financial Officer\nIR@aezsinc.com\n843-900-3201\nSource:Aeterna Zentaris Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=ln9gzyWYEkHpYVwOGqAwCH9KSc2RKnigum64px7KwuMKc7bhAWocrMChaNBjg2asBOerBEnQswWqG2sSwkjsOA==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/94b0ce1a-b66e-4aab-a178-2f2166ec00e5", "https://www.globenewswire.com/Tracker?data=iRg4qrGH4eAyUemgjCjSFzIt55fyrv4EVaKX5Md66KJzHcHMkOxN37bskFU7jIbbCylGv_b7fUcG3Luw06ia9w=="], "published": "2018-05-02T01:05:00.000+03:00", "crawled": "2018-05-02T02:19:13.020+03:00", "highlightTitle": ""}